epirubicin has been researched along with Carcinoma, Lobular in 60 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 3 (5.00) | 18.2507 |
| 2000's | 25 (41.67) | 29.6817 |
| 2010's | 29 (48.33) | 24.3611 |
| 2020's | 3 (5.00) | 2.80 |
| Authors | Studies |
|---|---|
| Broeks, A; Cimino-Mathews, A; Daletzakis, A; de Boo, L; Hooijberg, E; Horlings, HM; Kok, M; Linn, S; Loncova, Z; Lubeck, Y; Opdam, M; Rieder, D; Sanders, J; Sobral-Leite, M; Trajanoski, Z; van de Vijver, K; van der Wiel, R; van Rossum, A; van Tinteren, H; Vollebergh, M | 1 |
| Fujisawa, T; Higaki, K; Ishiguro, H; Kadoya, T; Kaneko, K; Masuda, N; Matsunami, N; Mizutani, M; Morimoto, T; Morita, S; Ohno, S; Ohtani, S; Sato, N; Takahashi, M; Takano, T; Tanaka-Mizuno, S; Toi, M; Yamamoto, Y; Yanagita, Y | 1 |
| Huang, L; Meng, L; Xu, Y; Zhang, W | 1 |
| Chen, J; Huan, Y; Li, D; Wang, J; Wang, L; Wang, T; Yao, Q; Yu, M; Zhang, J; Zhou, X | 1 |
| Barinoff, J; Bauerfeind, I; Belau, A; Clemens, M; Conrad, B; Diel, IJ; Elling, D; Forstbauer, H; Harbeck, N; Huober, J; Jackisch, C; Kreienberg, R; Loibl, S; Lück, HJ; Möbus, V; Müller, V; Nekljudova, V; Noeding, S; Schmidt, M; Schneeweiss, A; Thomssen, C; Untch, M; von Minckwitz, G | 1 |
| Alba, E; de la Torre-Cabrera, C; Fernández, M; Fernández-Navarro, M; Jaén-Morago, A; Pascual, J; Plata-Fernández, Y; Ramirez-Tortosa, C; Sánchez-Muñoz, A; Sánchez-Rovira, P | 1 |
| Champagne, C; Gaillot-Petit, N; Guilbert, P; Lamberth, F; Looten-Vieren, L; Nguyen, TD | 1 |
| Ameye, L; Bozovic-Spasojevic, I; de Azambuja, E; Di Leo, A; Dolci, S; Larsimont, D; Loi, S; Paesmans, M; Piccart, M | 1 |
| Adachi, S; Endo, I; Ichikawa, Y; Ishikawa, T; Kida, K; Narui, K; Sasaki, T; Satake, T; Shimada, K; Shimizu, D; Sugae, S; Tanabe, M; Yamada, A | 1 |
| Kagara, N; Kim, SJ; Maruyama, N; Michishita, S; Naoi, Y; Noguchi, S; Shimazu, K; Shimoda, M; Shimomura, A; Sota, Y | 1 |
| Boukovinas, I; Georgoulias, V; Kakolyris, S; Kentepozidis, N; Malamos, N; Mavroudis, D; Papakotoulas, P; Saloustros, E; Ziras, N | 1 |
| Bachelot, T; Boher, JM; Delva, R; Dohollou, N; Eymard, JC; Fabbro, M; Ferrero, JM; Gonçalves, A; Leduc, B; Lemonnier, J; Lerebours, F; Linassier, C; Lotz, JP; Martin, AL; Mouret-Reynier, MA; Pierga, JY; Roché, H; Viens, P | 1 |
| Capelan, M; Lote, H; Mohammed, K; Papadimitraki, E; Redana, S; Ring, A; Sharp, A | 1 |
| Kang, Y; Li, J; Ma, Y; Ren, W; Zang, L; Zhang, S | 1 |
| Alunni-Fabbroni, M; Andergassen, U; Camara, O; de Gregorio, N; Decker, T; Fasching, PA; Fehm, TN; Friedl, TWP; Heinrich, G; Jaeger, B; Janni, W; Mahner, S; Ober, A; Pantel, K; Rack, BK; Schneeweiss, A; Schochter, F; Schramm, A; Trapp, E | 1 |
| Bowman, A; Coleman, RE; Dunn, JA; Earl, HM; Fernando, IN; Hiller, L; Howard, HC; Poole, CJ; Ritchie, DM; Wardley, AM | 1 |
| Agarwal, R; Ashley, S; Chua, S; Johnston, S; Jones, RL; O'Brien, M; Smith, IE; Walsh, G | 1 |
| Dubois, N; Myant, N; Willems, T | 1 |
| Boidot, R; Coudert, B; Fumoleau, P; Lizard-Nacol, S; Soubeyrand, MS; Vegran, F | 1 |
| Li, T; Liu, YH; Qin, XQ; Wang, YH; Ye, JM; Yin, HF; Zhang, H | 1 |
| Enomoto, T; Hayashi, K; Kajita, S; Kondo, Y; Kosaka, Y; Kuranami, M; Sengoku, N; Watanabe, M | 1 |
| Hirakawa, K; Ishikawa, T; Kashiwagi, S; Kato, Y; Kawajiri, H; Nakata, B; Noda, S; Onoda, N; Takashima, T | 1 |
| Balslev, E; Bernsdorf, M; Ejlertsen, B; Ingvar, C; Jakobsen, EH; Jörgensen, L; Kimper-Karl, ML; Kroman, N; Saetersdal, A; Tuxen, MK | 1 |
| Arriagada, R; Bourgier, C; Dunant, A; Heymann, S; Marsiglia, H; Mathieu, MC; Pessoa, EL; Spielmann, M; Uzan, C | 1 |
| Baak, JP; Gilje, B; Janssen, EA; Nordgård, O; Smaaland, R; Søiland, H; Tjensvoll, K | 1 |
| Baranzelli, MC; Bonneterre, J; Giard, S; Liem, X; Penel, N | 1 |
| Brodowicz, T; Csörgo, E; Kahán, Z; Kaizer, L; Lázár, G; Nikolényi, A; Ormándi, K; Sükösd, F; Thurzó, L; Uhercsák, G; Vörös, A | 1 |
| Beck, T; Camara, O; du Bois, A; Fasching, PA; Fett, W; Harbeck, N; Hasmüller, S; Höss, C; Kahlert, S; Konecny, GE; Kreienberg, R; Kühn, T; Lebeau, A; Loibl, S; Mehta, KM; Müller, V; Stickeler, E; Untch, M; von Minckwitz, G | 1 |
| Farkas, R; Horváth, OP; Kálmán, E; Kovács, G; Kövér, E; Pavlovics, G; Szalai, G; Tizedes, G; Zapf, I | 1 |
| Cui, SD; Li, LF; Li, WL; Liu, H; Liu, ZZ; Lu, ZD; Yang, H; Zhang, HW | 1 |
| Ahlgren, J; Asola, R; Auvinen, P; Bono, P; Helle, L; Huovinen, R; Joensuu, H; Jukkola-Vuorinen, A; Kataja, V; Kellokumpu-Lehtinen, PL; Kokko, R; Leinonen, M; Lindman, H; Nilsson, G; Nyandoto, P; Paija, O; Pajunen, M; Poikonen, P; Tanner, M; Villman, K | 1 |
| Breidenbach, M; Duda, V; Eichler, C; Gossmann, A; Harbeck, N; Hoopmann, M; Kates, RE; Ohlinger, R; Thomas, A; Warm, M | 1 |
| Chen, S; Fu, R; Gu, H; Li, Q; Wang, Y; Wu, H; Yuan, K; Zhang, K; Zhang, L | 1 |
| Guli, KZ; Guo, L; Hu, X; Li, X; Li, Y; Liu, W; Ma, Y; Wen, SJ; Yang, SE; Zhao, B | 1 |
| Blot, E; Bonneterre, J; Desauw, C; Fournier, C; Hornez, L; Kramar, A; Peyrat, JP; Révillion, F | 1 |
| Fersching, DM; Holdenrieder, S; Lehner, J; Nagel, D; Stötzer, OJ | 1 |
| Alba-Conejo, E; de la Torre-Cabrera, C; Fernández, M; Fernández-Navarro, M; Jaén-Morago, A; Llácer, C; Lomas-Garrido, M; Navarro-Perez, V; Plata-Fernández, YM; Ramirez-Tortosa, C; Sánchez-Muñoz, A; Sánchez-Rovira, P | 1 |
| Carrara, HH; Silva, LM; Takahashi, CS | 1 |
| Ahern, R; Archer, C; Dowsett, M; Krajewska, M; Krajewski, S; Naito, M; Parton, M; Reed, J; Smith, I | 1 |
| Buksmaui, S; Hausmaninger, H; Heinrich, B; Höffken, K; Krejcy, K; Miller, MA; Morack, G; Possinger, K; Wallwiener, D | 1 |
| Allred, DC; Arpino, G; Ciocca, DR; Daguerre, P; Elledge, R; Gago, F; Leuzzi, M; Mohsin, SK; Vargas-Roig, L; Weiss, H | 1 |
| Hitzl, W; Peintinger, F; Prokop, E; Reitsamer, R | 1 |
| Bonneterre, J; Campone, M; Fargeot, P; Kerbrat, P; Luporsi, E; Monnier, A; Montcuquet, P; Namer, M; Roché, H; Romestaing, P | 1 |
| Baltas, D; Filipowicz, I; Hoffmann, G; Kolotas, C; Kontova, M; Kuner, RP; Kurek, R; Martin, T; Pollow, B; Roddiger, SJ; Rogge, B; Zamboglou, N | 1 |
| Angellier, E; Berdah, JF; Buyse, M; Fabbro, M; Greget, S; Herait, P; Jehl, V; Laplaige, P; Piedbois, P; Priou, F; Serin, D; Teissier, E; Valenza, B | 1 |
| Andre, F; Broglio, K; Buzdar, AU; Cristofanilli, M; Esteva, FJ; Fritsche, H; Hall, A; Hortobagyi, GN; Mazouni, C; Pusztai, L | 1 |
| Ames, FC; Babiera, GV; Feig, BW; Francis, A; Gilcrease, MZ; Hunt, KK; Kuerer, HM; Meric-Bernstam, F; Ross, MI; Shen, J | 1 |
| Galid, A; Gnant, M; Greil, R; Haid, A; Jakesz, R; Klug, E; Kubista, E; Kwasny, W; Lang, A; Luschin-Ebengreuth, G; Menzel, C; Mlineritsch, B; Pöstlberger, S; Rudas, M; Samonigg, H; Singer, CF; Steger, GG; Tausch, C; Wenzel, C | 1 |
| Adjadj, DJ; Aubard, Y; Benyoub, A; Bonnier, P; Clavère, P; Genet, D; Juin, P; Labourey, JL; Lebrun-Ly, V; Lejeune, C; Martin, J; Piana, L; Tubiana-Mathieu, N; Venat-Bouvet, L | 1 |
| Hamaoka, T; Hayashi, N; Kawasaki, T; Kikuchi, M; Nakamura, S; Suzuki, K; Tsugawa, K; Tsunoda-Shimizu, H; Yagata, H | 1 |
| Hao, XM; Hui, R; Zhang, J; Zhang, M | 1 |
| Arima, N; Iwase, H; Kai, K; Miyayama, H; Nishimura, R; Yamamoto, Y | 1 |
| Adrover, E; Alba, E; Almenar, S; Alvarez, I; Alvarez, JV; Antón, A; Aranda, E; Baena, JM; Calvo, L; Crespo, C; de Alava, E; García Puche, JL; Gonzalez, S; González-Palacios, JF; Gracia Marco, JM; Guitián, MD; Lluch, A; López García-Asenjo, JA; López-Vega, JM; Martín, M; Mayordomo, JI; Mel, JR; Modolell, A; Munárriz, B; Palacios, J; Pelegrí, A; Plazaola, A; Ramos, M; Rodríguez, CA; Rodríguez-Lescure, A; Ruiz, A; Ruiz-Borrego, M; Sánchez-Rovira, P; Seguí, MA; Vera, F | 1 |
| Bastert, G; Huober, J; Junkermann, H; Kaufmann, M; Leppien, G; Otto, HF; Schmid, H; Sinn, HP | 1 |
| Berger, C; Body, G; Bougnoux, P; Calais, G; Chapet, S; Descamps, P; Lansac, J; Le Floch, O; Reynaud-Bougnoux, A | 1 |
| Junkermann, H; Schmid, H; Sinn, HP; Wallwiener, D | 1 |
| Avril, N; Dose, J; Graeff, H; Jänicke, F; Kuhn, W; Nährig, J; Römer, W; Sattler, D; Schelling, M; Schwaiger, M; Werner, M | 1 |
| Hlawatsch, A; Hoffmann, G; Kuner, RP; Teifke, A; Thelen, M; Zamboglou, N | 1 |
| Haegele, P; Lehmann, S; Moyses, B; Petit, T; Rodier, JF; Schraub, S; Velten, M | 1 |
| Gnant, MF; Jakesz, R; Locker, GJ; Rudas, M; Schmidinger, M; Steger, GG; Taucher, S; Wenzel, C | 1 |
25 trial(s) available for epirubicin and Carcinoma, Lobular
| Article | Year |
|---|---|
Tumour-infiltrating lymphocytes (TILs) and BRCA-like status in stage III breast cancer patients randomised to adjuvant intensified platinum-based chemotherapy versus conventional chemotherapy.
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Tumor; BRCA1 Protein; BRCA2 Protein; Carboplatin; Carcinoma, Ductal, Breast; Carcinoma, Lobular; Chemotherapy, Adjuvant; Cyclophosphamide; Epirubicin; Female; Fluorouracil; Follow-Up Studies; Humans; Lymphocytes, Tumor-Infiltrating; Mutation; Neoplasm Recurrence, Local; Neoplasm Staging; Receptor, ErbB-2; Receptors, Estrogen; Receptors, Progesterone; Retrospective Studies; Survival Rate; Thiotepa; Triple Negative Breast Neoplasms | 2020 |
A randomized study comparing docetaxel/cyclophosphamide (TC), 5-fluorouracil/epirubicin/cyclophosphamide (FEC) followed by TC, and TC followed by FEC for patients with hormone receptor-positive HER2-negative primary breast cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Carcinoma, Ductal, Breast; Carcinoma, Lobular; Cyclophosphamide; Docetaxel; Epirubicin; Female; Fluorouracil; Follow-Up Studies; Humans; Middle Aged; Prognosis; Receptor, ErbB-2; Receptors, Estrogen; Receptors, Progesterone; Survival Rate; Young Adult | 2020 |
Neoadjuvant rh-endostatin, docetaxel and epirubicin for breast cancer: efficacy and safety in a prospective, randomized, phase II study.
Topics: Adolescent; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Carcinoma, Ductal, Breast; Carcinoma, Lobular; Docetaxel; Endostatins; Epirubicin; Female; Follow-Up Studies; Humans; Middle Aged; Neoadjuvant Therapy; Neoplasm Staging; Prognosis; Prospective Studies; Quality of Life; Taxoids; Young Adult | 2013 |
German adjuvant intergroup node-positive study: a phase III trial to compare oral ibandronate versus observation in patients with high-risk early breast cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Capecitabine; Carcinoma, Ductal, Breast; Carcinoma, Lobular; Chemotherapy, Adjuvant; Cyclophosphamide; Deoxycytidine; Diphosphonates; Epirubicin; Female; Fluorouracil; Follow-Up Studies; Germany; Humans; Ibandronic Acid; Middle Aged; Neoplasm Grading; Neoplasm Staging; Paclitaxel; Prognosis; Survival Rate; Young Adult | 2013 |
Tumor histological subtyping determined by hormone receptors and HER2 status defines different pathological complete response and outcome to dose-dense neoadjuvant chemotherapy in breast cancer patients.
Topics: Adult; Aged; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Carcinoma, Ductal, Breast; Carcinoma, Lobular; Chemotherapy, Adjuvant; Cyclophosphamide; Deoxycytidine; Doxorubicin; Epirubicin; Female; Follow-Up Studies; Gemcitabine; Humans; Immunoenzyme Techniques; Middle Aged; Neoadjuvant Therapy; Neoplasm Staging; Paclitaxel; Prognosis; Prospective Studies; Receptor, ErbB-2; Receptors, Estrogen; Receptors, Progesterone; Remission Induction; Survival Rate; Trastuzumab | 2014 |
Six versus 12 months of adjuvant trastuzumab in combination with dose-dense chemotherapy for women with HER2-positive breast cancer: a multicenter randomized study by the Hellenic Oncology Research Group (HORG).
Topics: Adolescent; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Tumor; Breast Neoplasms; Carcinoma, Ductal, Breast; Carcinoma, Lobular; Cyclophosphamide; Docetaxel; Epirubicin; Female; Fluorouracil; Follow-Up Studies; Humans; Immunoenzyme Techniques; Middle Aged; Neoplasm Grading; Prognosis; Receptor, ErbB-2; Survival Rate; Taxoids; Time Factors; Trastuzumab; Young Adult | 2015 |
UNICANCER-PEGASE 07 study: a randomized phase III trial evaluating postoperative docetaxel-5FU regimen after neoadjuvant dose-intense chemotherapy for treatment of inflammatory breast cancer.
Topics: Adult; Antineoplastic Agents, Hormonal; Antineoplastic Combined Chemotherapy Protocols; Axilla; Carcinoma, Ductal, Breast; Carcinoma, Lobular; Chemoradiotherapy, Adjuvant; Chemotherapy, Adjuvant; Cyclophosphamide; Disease-Free Survival; Docetaxel; Epirubicin; Female; Fluorouracil; Humans; Inflammatory Breast Neoplasms; Lymph Node Excision; Mastectomy; Middle Aged; Neoadjuvant Therapy; Receptor, ErbB-2; Receptors, Estrogen; Receptors, Progesterone; Taxoids | 2015 |
Prevalence of Circulating Tumor Cells After Adjuvant Chemotherapy With or Without Anthracyclines in Patients With HER2-negative, Hormone Receptor-positive Early Breast Cancer.
Topics: Adult; Aged; Anthracyclines; Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Tumor; Breast Neoplasms; Carcinoma, Ductal, Breast; Carcinoma, Lobular; Chemotherapy, Adjuvant; Cyclophosphamide; Docetaxel; Epirubicin; Female; Fluorouracil; Follow-Up Studies; Humans; Middle Aged; Neoplasm Invasiveness; Neoplastic Cells, Circulating; Prevalence; Prognosis; Receptor, ErbB-2; Receptors, Estrogen; Receptors, Progesterone; Survival Rate; Taxoids; Young Adult | 2017 |
tAnGo: a randomised phase III trial of gemcitabine in paclitaxel-containing, epirubicin/cyclophosphamide-based, adjuvant chemotherapy for early breast cancer: a prospective pulmonary, cardiac and hepatic function evaluation.
Topics: Adenocarcinoma; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Carcinoma, Ductal, Breast; Carcinoma, Lobular; Chemotherapy, Adjuvant; Cyclophosphamide; Deoxycytidine; Disease-Free Survival; Epirubicin; Female; Gemcitabine; Heart; Heart Function Tests; Humans; Liver; Liver Function Tests; Lung; Paclitaxel; Prospective Studies; Respiratory Function Tests; Survival Rate | 2008 |
A randomised pilot Phase II study of doxorubicin and cyclophosphamide (AC) or epirubicin and cyclophosphamide (EC) given 2 weekly with pegfilgrastim (accelerated) vs 3 weekly (standard) for women with early breast cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Carcinoma, Ductal, Breast; Carcinoma, Lobular; Chemotherapy, Adjuvant; Cyclophosphamide; Doxorubicin; Drug Therapy, Combination; Epirubicin; Feasibility Studies; Female; Filgrastim; Granulocyte Colony-Stimulating Factor; Heart; Humans; Maximum Tolerated Dose; Middle Aged; Neoadjuvant Therapy; Neoplasm Staging; Neutropenia; Patient Selection; Pilot Projects; Polyethylene Glycols; Prognosis; Recombinant Proteins; Survival Rate; Treatment Outcome | 2009 |
Variations in gene expression and response to neoadjuvant chemotherapy in breast carcinoma.
Topics: Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Tumor; Breast Neoplasms; Carcinoma, Ductal, Breast; Carcinoma, Lobular; Cyclophosphamide; Docetaxel; Epirubicin; Female; Fluorouracil; Gene Expression Profiling; Gene Expression Regulation, Neoplastic; Humans; Neoadjuvant Therapy; Oligonucleotide Array Sequence Analysis; Reverse Transcriptase Polymerase Chain Reaction; RNA, Messenger; Taxoids; Treatment Outcome | 2009 |
Effect of adding gefitinib to neoadjuvant chemotherapy in estrogen receptor negative early breast cancer in a randomized phase II trial.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Carcinoma, Ductal, Breast; Carcinoma, Lobular; Cyclophosphamide; Double-Blind Method; Epirubicin; Female; Fever; Gefitinib; Humans; Leukopenia; Middle Aged; Neoadjuvant Therapy; Neutropenia; Quinazolines; Receptors, Estrogen; Research Design; Treatment Outcome; Tumor Burden | 2011 |
Mitotic activity and bone marrow micrometastases have independent prognostic value in node positive breast cancer patients.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Bone Marrow Neoplasms; Breast Neoplasms; Carcinoma, Ductal, Breast; Carcinoma, Lobular; Cisplatin; Cyclophosphamide; Disease-Free Survival; Epirubicin; Female; Fluorouracil; Follow-Up Studies; Humans; Kaplan-Meier Estimate; Lymphatic Metastasis; Methotrexate; Middle Aged; Mitotic Index; Neoplasm Micrometastasis; Prognosis; Tamoxifen; Treatment Outcome | 2011 |
Pathologic complete response after neoadjuvant chemotherapy plus trastuzumab predicts favorable survival in human epidermal growth factor receptor 2-overexpressing breast cancer: results from the TECHNO trial of the AGO and GBG study groups.
Topics: Adult; Aged; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Carcinoma, Ductal, Breast; Carcinoma, Lobular; Chemotherapy, Adjuvant; Cohort Studies; Cyclophosphamide; Epirubicin; Female; Follow-Up Studies; Humans; Middle Aged; Neoadjuvant Therapy; Neoplasm Invasiveness; Paclitaxel; Prospective Studies; Receptor, ErbB-2; Remission Induction; Survival Rate; Trastuzumab; Treatment Outcome; Young Adult | 2011 |
Adjuvant capecitabine, docetaxel, cyclophosphamide, and epirubicin for early breast cancer: final analysis of the randomized FinXX trial.
Topics: Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Tumor; Breast Neoplasms; Capecitabine; Carcinoma, Ductal, Breast; Carcinoma, Lobular; Chemotherapy, Adjuvant; Cyclophosphamide; Deoxycytidine; Disease-Free Survival; Docetaxel; Drug Administration Schedule; Epirubicin; Female; Finland; Fluorouracil; Follow-Up Studies; Humans; Lymphatic Metastasis; Mastectomy; Middle Aged; Neoplasm Grading; Neoplasm Staging; Prospective Studies; Survival Analysis; Taxoids; Treatment Outcome | 2012 |
The role of immunohistochemistry in breast cancer patients treated with neoadjuvant chemotherapy: an old tool with an enduring prognostic value.
Topics: Adolescent; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Tumor; Breast Neoplasms; Carcinoma, Ductal, Breast; Carcinoma, Lobular; Cyclophosphamide; Deoxycytidine; Doxorubicin; Epirubicin; Female; Follow-Up Studies; Gemcitabine; Humans; Immunoenzyme Techniques; Ki-67 Antigen; Middle Aged; Neoadjuvant Therapy; Neoplasm Staging; Paclitaxel; Prognosis; Prospective Studies; Receptor, ErbB-2; Receptors, Estrogen; Receptors, Progesterone; Remission Induction; Retrospective Studies; Survival Rate; Young Adult | 2013 |
Gemcitabine combined with epirubicin in the treatment of patients with locally advanced or metastatic breast cancer: a phase II study.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Carcinoma, Ductal, Breast; Carcinoma, Lobular; Deoxycytidine; Epirubicin; Female; Gemcitabine; Humans; Middle Aged; Neoplasm Metastasis; Survival Analysis | 2004 |
Pathological complete response rates comparing 3 versus 6 cycles of epidoxorubicin and docetaxel in the neoadjuvant setting of patients with stage II and III breast cancer.
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Carcinoma, Ductal, Breast; Carcinoma, Lobular; Chemotherapy, Adjuvant; Docetaxel; Drug Administration Schedule; Epirubicin; Female; Glucuronates; Granulocyte Colony-Stimulating Factor; Humans; Middle Aged; Neoadjuvant Therapy; Neoplasm Invasiveness; Neoplasm Staging; Prospective Studies; Receptor, ErbB-2; Remission Induction; Taxoids; Treatment Outcome | 2005 |
Improved disease-free survival with epirubicin-based chemoendocrine adjuvant therapy compared with tamoxifen alone in one to three node-positive, estrogen-receptor-positive, postmenopausal breast cancer patients: results of French Adjuvant Study Group 02
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Carcinoma, Ductal, Breast; Carcinoma, Lobular; Chemotherapy, Adjuvant; Cyclophosphamide; Disease-Free Survival; Epirubicin; Female; Fluorouracil; Humans; Lymph Nodes; Middle Aged; Neoplasms, Second Primary; Postmenopause; Receptors, Estrogen; Retrospective Studies; Survival Rate; Tamoxifen | 2006 |
Dose-dense adjuvant chemotherapy in node-positive breast cancer: docetaxel followed by epirubicin/cyclophosphamide (T/EC), or the reverse sequence (EC/T), every 2 weeks, versus docetaxel, epirubicin and cyclophosphamide (TEC) every 3 weeks. AERO B03 rando
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Carcinoma, Ductal, Breast; Carcinoma, Lobular; Cyclophosphamide; Docetaxel; Dose-Response Relationship, Drug; Epirubicin; Feasibility Studies; Female; Humans; Lymph Nodes; Lymphatic Metastasis; Middle Aged; Neoplasm Invasiveness; Neoplasm Staging; Prognosis; Survival Rate; Taxoids; Treatment Outcome | 2007 |
Kinetics of serum HER-2/neu changes in patients with HER-2-positive primary breast cancer after initiation of primary chemotherapy.
Topics: Adult; Aged; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Tumor; Breast Neoplasms; Carcinoma, Ductal, Breast; Carcinoma, Lobular; Cyclophosphamide; Epirubicin; Female; Fluorouracil; Humans; Kinetics; Middle Aged; Neoadjuvant Therapy; Prognosis; Prospective Studies; Receptor, ErbB-2; Trastuzumab | 2007 |
Pathologic complete response with six compared with three cycles of neoadjuvant epirubicin plus docetaxel and granulocyte colony-stimulating factor in operable breast cancer: results of ABCSG-14.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Axilla; Breast Neoplasms; Carcinoma, Ductal, Breast; Carcinoma, Lobular; Chemotherapy, Adjuvant; Docetaxel; Epirubicin; Female; Granulocyte Colony-Stimulating Factor; Humans; Lymphatic Metastasis; Middle Aged; Neoadjuvant Therapy; Neoplasm Staging; Prospective Studies; Taxoids | 2007 |
[Comparison of tolerance and toxicity of CEF-100 regimen versus CEF-60 regimen as adjuvant therapy for breast cancer].
Topics: Adult; Alanine Transaminase; Antineoplastic Combined Chemotherapy Protocols; Aspartate Aminotransferases; Breast Neoplasms; Carcinoma, Ductal, Breast; Carcinoma, Lobular; Chemotherapy, Adjuvant; Cyclophosphamide; Epirubicin; Female; Fluorouracil; Follow-Up Studies; Humans; Leukopenia; Middle Aged; Neutropenia; Vomiting | 2007 |
Randomized phase 3 trial of fluorouracil, epirubicin, and cyclophosphamide alone or followed by Paclitaxel for early breast cancer.
Topics: Adult; Aged; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Tumor; Breast Neoplasms; Carcinoma, Ductal, Breast; Carcinoma, Lobular; Cyclophosphamide; Disease-Free Survival; Drug Administration Schedule; Epirubicin; Female; Fluorouracil; Humans; Immunohistochemistry; In Situ Hybridization, Fluorescence; Infusions, Intravenous; Kaplan-Meier Estimate; Middle Aged; Neoplasm Staging; Paclitaxel; Predictive Value of Tests; Prognosis; Proportional Hazards Models; Receptor, ErbB-2; Receptors, Estrogen; Receptors, Progesterone; Treatment Outcome | 2008 |
Combined analysis of two phase II trials in patients with primary and advanced breast cancer with epidoxorubicin and docetaxel+granulocyte colony stimulating factor.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Carcinoma, Ductal, Breast; Carcinoma, Lobular; Docetaxel; Epirubicin; Female; Granulocyte Colony-Stimulating Factor; Humans; Menopause; Middle Aged; Neoadjuvant Therapy; Paclitaxel; Palliative Care; Prospective Studies; Survival Rate; Taxoids | 2002 |
35 other study(ies) available for epirubicin and Carcinoma, Lobular
| Article | Year |
|---|---|
Incidence of interstitial pneumonitis in breast cancer patients treated with pegylated liposomal doxorubicin.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Carcinoma, Ductal, Breast; Carcinoma, Lobular; China; Cyclophosphamide; Doxorubicin; Epirubicin; Female; Follow-Up Studies; Humans; Incidence; Lung Diseases, Interstitial; Middle Aged; Neoplasm Invasiveness; Polyethylene Glycols; Prognosis; Retrospective Studies | 2020 |
[Potential indications for helical tomotherapy in breast cancers].
Topics: Adult; Aged; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Carcinoma, Ductal, Breast; Carcinoma, Lobular; Combined Modality Therapy; Cyclophosphamide; Docetaxel; Epirubicin; Female; Fluorouracil; Funnel Chest; Hodgkin Disease; Humans; Middle Aged; Neoplasms, Multiple Primary; Neoplasms, Second Primary; Obesity; Radiotherapy Planning, Computer-Assisted; Radiotherapy, Conformal; Radiotherapy, Intensity-Modulated; Taxoids | 2014 |
Prognostic, predictive abilities and concordance of BCL2 and TP53 protein expression in primary breast cancers and axillary lymph-nodes: a retrospective analysis of the Belgian three arm study evaluating anthracycline vs CMF adjuvant chemotherapy.
Topics: Adult; Aged; Antibiotics, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Axilla; Biomarkers, Tumor; Breast Neoplasms; Carcinoma, Ductal, Breast; Carcinoma, Lobular; Chemotherapy, Adjuvant; Cisplatin; Disease-Free Survival; Epirubicin; Female; Fluorouracil; Humans; Lymph Nodes; Methotrexate; Middle Aged; Prognosis; Proto-Oncogene Proteins c-bcl-2; Retrospective Studies; Treatment Outcome; Tumor Suppressor Protein p53 | 2014 |
Outcomes of immediate perforator flap reconstruction after skin-sparing mastectomy following neoadjuvant chemotherapy.
Topics: Adult; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Carboplatin; Carcinoma, Ductal, Breast; Carcinoma, Intraductal, Noninfiltrating; Carcinoma, Lobular; Chemotherapy, Adjuvant; Cohort Studies; Cyclophosphamide; Docetaxel; Epirubicin; Etoposide; Female; Fluorouracil; Humans; Mammaplasty; Mastectomy, Subcutaneous; Middle Aged; Neoadjuvant Therapy; Paclitaxel; Perforator Flap; Retrospective Studies; Taxoids; Trastuzumab; Treatment Outcome; Young Adult | 2015 |
Prediction of pathological complete response to neoadjuvant chemotherapy by magnetic resonance imaging in breast cancer patients.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Carcinoma, Ductal, Breast; Carcinoma, Lobular; Cohort Studies; Cyclophosphamide; Decision Support Techniques; Epirubicin; Estrogen Receptor alpha; Female; Fluorouracil; Humans; Magnetic Resonance Imaging; Mastectomy; Mastectomy, Segmental; Middle Aged; Neoadjuvant Therapy; Neoplasm Grading; Neoplasm Staging; Paclitaxel; Prognosis; Receptor, ErbB-2; Receptors, Progesterone; Retrospective Studies; Treatment Outcome; Tumor Burden; Young Adult | 2015 |
Rates of major complications during neoadjuvant and adjuvant chemotherapy for early breast cancer: An off study population.
Topics: Acute Coronary Syndrome; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Carcinoma, Ductal, Breast; Carcinoma, Lobular; Chemotherapy-Induced Febrile Neutropenia; Chemotherapy, Adjuvant; Cyclophosphamide; Docetaxel; Dose-Response Relationship, Drug; Epirubicin; Female; Fluorouracil; Humans; Incidence; Mastectomy; Mastectomy, Segmental; Middle Aged; Neoadjuvant Therapy; Neoplasm Staging; Paclitaxel; Pulmonary Embolism; Retrospective Studies; Risk Factors; Sentinel Lymph Node Biopsy; Stroke; Taxoids; Thromboembolism; Venous Thrombosis | 2016 |
Combination of shear wave elastography and Ki-67 index as a novel predictive modality for the pathological response to neoadjuvant chemotherapy in patients with invasive breast cancer.
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Carcinoma, Ductal, Breast; Carcinoma, Lobular; Cyclophosphamide; Docetaxel; Elasticity Imaging Techniques; Epirubicin; Female; Fluorouracil; Humans; Ki-67 Antigen; Mastectomy; Mastectomy, Segmental; Middle Aged; Neoadjuvant Therapy; Neoplasm Staging; Neoplasm, Residual; Prospective Studies; Taxoids; Trastuzumab; Treatment Outcome; Tumor Burden; Ultrasonography, Mammary | 2016 |
[Ovarian metastasis of breast cancer: a case report. Role of cytoreductive surgery].
Topics: Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Tumor; Breast Neoplasms; Carcinoma, Lobular; Cyclophosphamide; Epirubicin; Female; Fluorouracil; Humans; Mastectomy, Segmental; Middle Aged; Ovarian Neoplasms | 2009 |
[Effect of neoadjuvant chemotherapy on histologic grade and expression of biological markers in breast cancer].
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Tumor; Breast Neoplasms; Carcinoma, Ductal, Breast; Carcinoma, Lobular; Docetaxel; Epirubicin; Female; Humans; Ki-67 Antigen; Middle Aged; Neoadjuvant Therapy; Paclitaxel; Receptor, ErbB-2; Receptors, Estrogen; Receptors, Progesterone; Retrospective Studies; Taxoids | 2009 |
[A long-term survival case of progressive breast cancer detected in gastric metastasis].
Topics: Antibiotics, Antineoplastic; Antineoplastic Agents, Alkylating; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Carcinoma, Lobular; Cyclophosphamide; Epirubicin; Female; Humans; Middle Aged; Stomach Neoplasms | 2010 |
[A case of multicentric breast cancer in which an effect of neoadjuvant chemotherapy had a disparity].
Topics: Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Carcinoma, Ductal, Breast; Carcinoma, Lobular; Cyclophosphamide; Epirubicin; Female; Fluorouracil; Humans; Middle Aged; Neoadjuvant Therapy; Neoplasms, Multiple Primary | 2010 |
Exclusive alternating chemotherapy and radiotherapy in nonmetastatic inflammatory breast cancer: 20 years of follow-up.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Brachial Plexus Neuropathies; Carcinoma, Ductal, Breast; Carcinoma, Lobular; Combined Modality Therapy; Cyclophosphamide; Dose Fractionation, Radiation; Doxorubicin; Drug Administration Schedule; Epirubicin; Female; Fibrosis; Fluorouracil; Follow-Up Studies; Heart; Humans; Inflammatory Breast Neoplasms; Methotrexate; Middle Aged; Neoplasm Recurrence, Local; Radiation Injuries; Radiation Pneumonitis; Survival Rate; Tamoxifen; Time Factors; Vincristine | 2012 |
Is adjuvant chemotherapy useful in lobular breast cancer patients?
Topics: Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Carcinoma, Lobular; Chemotherapy, Adjuvant; Cyclophosphamide; Disease-Free Survival; Epirubicin; Female; Fluorouracil; Humans; Retrospective Studies | 2011 |
Tumor topoisomerase II alpha status and response to anthracycline-based neoadjuvant chemotherapy in breast cancer.
Topics: Adult; Antigens, Neoplasm; Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Tumor; Breast Neoplasms; Capecitabine; Carcinoma, Ductal, Breast; Carcinoma, Lobular; Chemotherapy, Adjuvant; Deoxycytidine; Disease-Free Survival; DNA Topoisomerases, Type II; DNA-Binding Proteins; Docetaxel; Epirubicin; Female; Fluorouracil; Gene Expression; Genes, erbB-2; Humans; Immunochemistry; In Situ Hybridization, Fluorescence; Ki-67 Antigen; Middle Aged; Neoadjuvant Therapy; Poly-ADP-Ribose Binding Proteins; Receptors, Estrogen; Receptors, Progesterone; Retrospective Studies; Survival Analysis; Taxoids; Treatment Outcome | 2011 |
[Primary systemic therapy in breast cancer patients (2007-2010)].
Topics: Adult; Age Factors; Aged; Antineoplastic Combined Chemotherapy Protocols; Axilla; Breast Neoplasms; Carcinoma; Carcinoma, Ductal, Breast; Carcinoma, Intraductal, Noninfiltrating; Carcinoma, Lobular; Carcinoma, Medullary; Carcinoma, Papillary; Chemotherapy, Adjuvant; Cyclophosphamide; Docetaxel; Drug Administration Schedule; Epirubicin; Female; Fluorouracil; Humans; Lymphatic Metastasis; Mastectomy; Mastectomy, Segmental; Middle Aged; Neoadjuvant Therapy; Neoplasm Grading; Neoplasm Staging; Neoplasm, Residual; Radiography; Retrospective Studies; Taxoids; Treatment Outcome | 2011 |
[Predictive value of (99)Tc(m)-MIBI scintimammography in evaluation of the efficacy of neoadjuvant chemotherapy in patients with operable breast cancer].
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Carcinoma, Ductal, Breast; Carcinoma, Lobular; Chemotherapy, Adjuvant; Cyclophosphamide; Disease-Free Survival; Epirubicin; Etoposide; Female; Fluorouracil; Follow-Up Studies; Humans; Middle Aged; Neoadjuvant Therapy; Neoplasm Staging; Predictive Value of Tests; Radionuclide Imaging; Radiopharmaceuticals; Remission Induction; Taxoids; Technetium Tc 99m Sestamibi | 2011 |
3D breast ultrasound: a significant predictor in breast cancer reduction under pre-operative chemotherapy.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Carcinoma, Ductal, Breast; Carcinoma, Lobular; Carcinoma, Medullary; Chemotherapy, Adjuvant; Epirubicin; Female; Humans; Imaging, Three-Dimensional; Middle Aged; Neoplasm Staging; Paclitaxel; Preoperative Care; Prognosis; Remission Induction; Ultrasonography, Mammary | 2011 |
Identification of potential markers related to neoadjuvant chemotherapy sensitivity of breast cancer by SELDI-TOF MS.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Pharmacological; Biomarkers, Tumor; Biopsy, Needle; Breast Neoplasms; Carcinoma, Ductal, Breast; Carcinoma, Lobular; Complement C3a; Cyclophosphamide; Cytarabine; Drug Resistance, Neoplasm; Epirubicin; Female; Humans; Middle Aged; Neoadjuvant Therapy; Neoplasm Staging; Proteomics; Reproducibility of Results; Spectrometry, Mass, Matrix-Assisted Laser Desorption-Ionization | 2012 |
[Correlation of expression of Survivin, BCRP and HER-2 genes with therapeutic response of TE regimen neoadjuvant chemotherapy in breast cancer patients].
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; ATP Binding Cassette Transporter, Subfamily G, Member 2; ATP-Binding Cassette Transporters; Breast Neoplasms; Carcinoma, Ductal, Breast; Carcinoma, Lobular; Disease Progression; Docetaxel; Epirubicin; Female; Humans; Inhibitor of Apoptosis Proteins; Mastectomy, Radical; Middle Aged; Neoadjuvant Therapy; Neoplasm Proteins; Receptor, ErbB-2; Remission Induction; RNA, Messenger; Survivin; Taxoids | 2011 |
Plasma and tissue proteomic prognostic factors of response in primary breast cancer patients receiving neoadjuvant chemotherapy.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Tumor; Blood Proteins; Breast Neoplasms; Carcinoma, Ductal, Breast; Carcinoma, Lobular; Cyclophosphamide; Docetaxel; Epirubicin; Female; Fluorouracil; Follow-Up Studies; Humans; Middle Aged; Neoadjuvant Therapy; Neoplasm Grading; Neoplasm Staging; Prognosis; Protein Array Analysis; Proteomics; Spectrometry, Mass, Matrix-Assisted Laser Desorption-Ionization; Survival Rate; Taxoids | 2013 |
Plasma DNA integrity indicates response to neoadjuvant chemotherapy in patients with locally confined breast cancer.
Topics: Antineoplastic Agents; Biomarkers, Tumor; Breast Neoplasms; Carcinoma, Ductal, Breast; Carcinoma, Lobular; Cyclophosphamide; DNA; Docetaxel; Epirubicin; Female; Follow-Up Studies; Humans; Neoadjuvant Therapy; Taxoids; Treatment Outcome | 2013 |
Study of chromosome damage in patients with breast cancer treated by two antineoplastic treatments.
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Carcinoma, Ductal, Breast; Carcinoma, Lobular; Cell Division; Chromosome Aberrations; Chromosomes, Human; Cyclophosphamide; DNA Damage; Drug Administration Schedule; Epirubicin; Female; Fluorouracil; Humans; Methotrexate; Middle Aged; Mitotic Index; Sister Chromatid Exchange | 2002 |
Coordinate expression of apoptosis-associated proteins in human breast cancer before and during chemotherapy.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Biomarkers, Tumor; Breast Neoplasms; Carcinoma, Ductal, Breast; Carcinoma, Lobular; Caspase 3; Caspase 6; Caspases; Cisplatin; Cyclophosphamide; Deoxyribonucleases; Doxorubicin; Epirubicin; Female; Fluorouracil; Humans; Immunoenzyme Techniques; Ki-67 Antigen; Middle Aged; Neoplasm Proteins; Poly-ADP-Ribose Binding Proteins; Proteins; Proto-Oncogene Proteins c-bcl-2; Receptor, ErbB-2; Receptors, Estrogen; Receptors, Progesterone; X-Linked Inhibitor of Apoptosis Protein | 2002 |
Predictive value of apoptosis, proliferation, HER-2, and topoisomerase IIalpha for anthracycline chemotherapy in locally advanced breast cancer.
Topics: Adult; Aged; Antibiotics, Antineoplastic; Antigens, Neoplasm; Apoptosis; Biomarkers, Tumor; Breast Neoplasms; Carcinoma, Ductal, Breast; Carcinoma, Lobular; Cell Proliferation; DNA Topoisomerases, Type II; DNA-Binding Proteins; Doxorubicin; Epirubicin; Female; Genes, erbB-2; Humans; Middle Aged; Neoplasm Staging; Pilot Projects; Predictive Value of Tests | 2005 |
Neoadjuvant interstitial high-dose-rate (HDR) brachytherapy combined with systemic chemotherapy in patients with breast cancer.
Topics: Adult; Aged; Antibiotics, Antineoplastic; Antineoplastic Agents, Alkylating; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Brachytherapy; Breast; Breast Neoplasms; Carcinoma, Ductal; Carcinoma, Lobular; Cisplatin; Combined Modality Therapy; Cyclophosphamide; Docetaxel; Dose Fractionation, Radiation; Doxorubicin; Epirubicin; Female; Fluorouracil; Follow-Up Studies; Humans; Lymphatic Metastasis; Mastectomy, Segmental; Methotrexate; Middle Aged; Neoadjuvant Therapy; Neoplasm Recurrence, Local; Neoplasm Staging; Radiotherapy Dosage; Radiotherapy Planning, Computer-Assisted; Retrospective Studies; Risk Factors; Taxoids; Time Factors; Tomography, X-Ray Computed; Treatment Outcome | 2006 |
Feasibility and accuracy of sentinel lymph node biopsy after preoperative chemotherapy in breast cancer patients with documented axillary metastases.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Axilla; Biopsy, Fine-Needle; Breast Neoplasms; Carcinoma, Ductal, Breast; Carcinoma, Lobular; Cyclophosphamide; Doxorubicin; Epirubicin; False Negative Reactions; Feasibility Studies; Female; Fluorouracil; Humans; Lymphatic Metastasis; Middle Aged; Neoplasm Invasiveness; Neoplasm Staging; Preoperative Care; Sentinel Lymph Node Biopsy; Time Factors; Ultrasonography, Mammary | 2007 |
Concomitant intensive chemoradiotherapy induction in non-metastatic inflammatory breast cancer: long-term follow-up.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Carcinoma, Ductal, Breast; Carcinoma, Lobular; Cisplatin; Combined Modality Therapy; Cyclophosphamide; Disease-Free Survival; Dose Fractionation, Radiation; Epirubicin; Female; Fluorouracil; Follow-Up Studies; Humans; Menopause; Middle Aged; Remission Induction; Survival Rate; Time Factors; Treatment Outcome | 2007 |
Determining the morphological features of breast cancer and predicting the effects of neoadjuvant chemotherapy via diagnostic breast imaging.
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Carcinoma, Ductal, Breast; Carcinoma, Lobular; Carcinoma, Papillary; Chemotherapy, Adjuvant; Cyclophosphamide; Diagnostic Imaging; Epirubicin; Female; Fluorouracil; Humans; Middle Aged; Neoadjuvant Therapy; Prognosis; Retrospective Studies; Stereoisomerism; Treatment Outcome | 2008 |
Pathological lymph node involvement at surgery is a significant predictive factor of recurrence in locally advanced breast cancer treated with concomitant epirubicin-docetaxel neoadjuvant chemotherapy: a cohort study.
Topics: Adult; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Axilla; Breast Neoplasms; Carcinoma, Ductal, Breast; Carcinoma, Lobular; Cohort Studies; Disease-Free Survival; Docetaxel; Epirubicin; Female; Humans; Lymphatic Metastasis; Middle Aged; Multivariate Analysis; Neoadjuvant Therapy; Neoplasm Recurrence, Local; Retrospective Studies; Taxoids | 2009 |
[Histologic regression of breast cancer after primary (neoadjuvant) chemotherapy].
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Carcinoma; Carcinoma, Ductal, Breast; Carcinoma, Lobular; Cell Division; Cell Survival; Chemotherapy, Adjuvant; Combined Modality Therapy; Cyclophosphamide; Dose-Response Relationship, Drug; Epirubicin; Female; Humans; Lymph Nodes; Lymphatic Metastasis; Middle Aged; Neoplasm Staging; Premedication | 1994 |
Conservative treatment feasibility with induction chemotherapy, surgery, and radiotherapy for patients with breast carcinoma larger than 3 cm.
Topics: Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Carcinoma, Ductal, Breast; Carcinoma, Lobular; Chemotherapy, Adjuvant; Cobalt Radioisotopes; Combined Modality Therapy; Cyclophosphamide; Epirubicin; Feasibility Studies; Female; Fluorouracil; Follow-Up Studies; Humans; Mastectomy, Modified Radical; Middle Aged; Mitoxantrone; Neoplasm Recurrence, Local; Neoplasm Staging; Remission Induction; Survival Rate; Tamoxifen; Treatment Failure; Vindesine | 1994 |
[Response evaluation with mammography and ultrasound].
Topics: Antineoplastic Combined Chemotherapy Protocols; Breast; Breast Neoplasms; Carcinoma, Ductal, Breast; Carcinoma, Lobular; Chemotherapy, Adjuvant; Combined Modality Therapy; Cyclophosphamide; Epirubicin; Female; Humans; Mammography; Neoplasm Staging; Treatment Outcome; Ultrasonography, Mammary | 1996 |
Positron emission tomography using [(18)F]Fluorodeoxyglucose for monitoring primary chemotherapy in breast cancer.
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Carcinoma, Ductal, Breast; Carcinoma, Lobular; Cyclophosphamide; Epirubicin; Female; Fluorodeoxyglucose F18; Humans; Middle Aged; Paclitaxel; Predictive Value of Tests; Prospective Studies; Radiopharmaceuticals; ROC Curve; Sensitivity and Specificity; Tomography, Emission-Computed | 2000 |
[MR mammography of response-control in primary chemo-brachytherapy in BCT-inoperable breast cancer].
Topics: Adult; Antibiotics, Antineoplastic; Antineoplastic Agents, Alkylating; Brachytherapy; Breast Neoplasms; Carcinoma, Ductal, Breast; Carcinoma, Lobular; Combined Modality Therapy; Contrast Media; Cyclophosphamide; Drug Therapy, Combination; Epirubicin; Female; Gadolinium DTPA; Humans; Image Enhancement; Magnetic Resonance Imaging; Middle Aged; Preoperative Care; Time Factors | 2001 |
Assessment of response by breast helical computed tomography to neoadjuvant chemotherapy in large inflammatory breast cancer.
Topics: Adult; Aged; Antibiotics, Antineoplastic; Antimetabolites, Antineoplastic; Antineoplastic Agents, Alkylating; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Biopsy, Needle; Carcinoma, Ductal, Breast; Carcinoma, Lobular; Cyclophosphamide; Docetaxel; Drug Monitoring; Epirubicin; Female; Fluorouracil; Humans; Mammography; Mastectomy; Middle Aged; Mitoxantrone; Neoadjuvant Therapy; Paclitaxel; Physical Examination; Taxoids; Tomography, X-Ray Computed; Treatment Outcome; Vinblastine; Vinorelbine | 2002 |